MedTrace Logo

Probiotics Regulate Intestinal Health and Alleviate Anxiety

NCT07353320 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2026-01-20

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled trial aimed primarily at investigating the effects of Weizmannia coagulans BC99 on alleviating anxiety and depression and the gut microbiota.

Conditions

  • Anxiety Depression

Interventions

DIETARY_SUPPLEMENT

probiotics group

The intervention lasted 8 weeks, with follow-ups at weeks 0 and 12.

DIETARY_SUPPLEMENT

Placebo Group

The intervention lasted 8 weeks, with follow-ups at weeks 0 and 12.

Sponsors & Collaborators

  • Wecare Probiotics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-10
Primary Completion
2024-06-05
Completion
2025-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07353320 on ClinicalTrials.gov